Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05441501 · ClinicalTrials.gov registry record · Phase 1
A Study of JNJ-80038114 in Participants With Advanced Stage Prostate Cancer
A Phase 1 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
NCT05441501 is a Phase 1 study that has completed, run by Janssen Research & Development. The registered enrollment target is 39 participants.
The verdict
NCT05441501, a Phase 1 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
Study Summary
The purpose of this study is to determine recommended phase 2 dose(s) (RP2Ds) of JNJ-80038114 in Part 1 (dose escalation) and to determine the safety at the RP2D(s) in Part 2 (dose expansion).
Interventions
- DRUG JNJ-80038114
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2022-11-15 |
| Est. Completion | 2024-03-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05441501
The ClinicalTrials.gov registry entry for NCT05441501 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which JNJ-80038114 is the first listed.
NCT05441501 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05441501 about?
NCT05441501 is a clinical study titled "A Study of JNJ-80038114 in Participants With Advanced Stage Prostate Cancer". The purpose of this study is to determine recommended phase 2 dose(s) (RP2Ds) of JNJ-80038114 in Part 1 (dose escalation) and to determine the safety at the RP2D(s) in Part 2 (dose expansion).
What is the current status of trial NCT05441501?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2022-11-15. Estimated completion is 2024-03-31.
What interventions are being tested in trial NCT05441501?
The interventions under investigation include: JNJ-80038114 (DRUG).
Who is sponsoring clinical trial NCT05441501?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.